论文部分内容阅读
目的观察奥扎格雷钠(丹奥)治疗急性脑梗死根据牛津郡社区脑卒中项目(OCSP)分类的临床疗效和安全性。方法将317例急性脑梗死患者,随机分为丹奥治疗组130例,对照组187例,进行 OCSP 分类,观察比较治疗前后临床神经功能缺损评分和不良反应。结果丹奥治疗组的有效率在前循环型中明显高于对照组(P<0.001),在其他型中无明显差别。丹奥治疗组中未发现明显不良反应。结论丹奥治疗前循环型脑梗死疗效显著,安全性良好。
Objective To observe the clinical efficacy and safety of ozagrel sodium (Danio) in the treatment of acute cerebral infarction according to Oxfordshire Community Stroke Project (OCSP). Methods A total of 317 patients with acute cerebral infarction were randomly divided into Danao treatment group (130 cases) and control group (187 cases). The OCSP classification was used to compare the clinical neurological deficit scores and adverse reactions before and after treatment. Results The effective rate of Danao treatment group was significantly higher than that of the control group (P <0.001) in the anterior circulation group, and no significant difference in other types. Danio treatment group found no significant adverse reactions. Conclusion Danio treatment of recurrent cerebral infarction with significant efficacy, good safety.